Unexplained or atypical thrombotic events, particularly in the absence of major cardiovascular risk factors, should prompt evaluation for MPNs, even if CBC findings appear normal, as MPNs may not present with obvious hematological abnormalities in early stages, making genetic testing and further investigations crucial. The presence of the JAK2 V617F mutation strengthens the suspicion of an MPN and may indicate a higher risk of both thrombosis and aneurysm formation. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.